Integrated Filing (Financial) for the quarter and the financial year ended on 31st March 2025

EBITDA margin expansionProfit growth above 25%Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+14.0%Reaction day

₹42.10

prior close

₹50.52

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+13.5% vs market

Pharmaceuticals peers, median of 148sector+0.4%+13.6% vs sector

On the reaction day the stock moved 13.5 pts more than Nifty Microcap 250 and 13.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

-2.0

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+14.0+0.6+13.5+0.4+13.6

Next day

+8.5+0.5+8.0+0.3+8.1

+21.1+0.8+20.3+0.5+20.6

+18.8+1.2+17.6+1.0+17.8

+18.8+1.5+17.3+0.6+18.2

+14.6+1.6+13.1-0.1+14.7

+15.9+1.8+14.1+0.1+15.8

15d

+15.9+3.3+12.6+1.5+14.4

+17.7+3.1+14.6-1.2+18.9

+56.8+2.3+54.5+0.6+56.2

-13.1+0.2-13.4-1.6-11.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kimia Biosciences reported a strong turnaround for FY25. Revenue from operations rose about 13% to ₹11,892 lakhs from ₹10,488 lakhs in FY24. The company swung from a loss before tax of ₹718 lakhs to a profit before tax of ₹1,363 lakhs, translating into a profit after tax of ₹961 lakhs versus a loss of ₹531 lakhs last year. EPS turned positive at ₹2.03 versus negative ₹1.12. Total equity improved sharply to ₹997 lakhs from just ₹33 lakhs, as the company cut long-term borrowings from ₹2,141 lakhs to ₹1,037 lakhs. Operating cash flow was healthy at ₹2,131 lakhs. Statutory auditor Neeraj Arora & Associates issued an unmodified (clean) opinion on the results.

Likely market impact

Positive for shareholders — the company returned to profitability, significantly deleveraged, and strengthened its balance sheet, though trade payables and receivables both grew sharply, indicating working-capital strain that investors should watch.